CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
์ข
๋ชฉ ์ฝ๋ CRMD
ํ์ฌ ์ด๋ฆCorMedix Inc
์์ฅ์ผMar 25, 2010
CEOMr. Joseph Todisco
์ง์ ์64
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃMar 25
์ฃผ์300 Connell Drive
๋์BERKELEY HEIGHTS
์ฆ๊ถ ๊ฑฐ๋์NASDAQ Global Market Consolidated
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ07922
์ ํ19085179500
์น์ฌ์ดํธhttps://cormedix.com/
์ข
๋ชฉ ์ฝ๋ CRMD
์์ฅ์ผMar 25, 2010
CEOMr. Joseph Todisco
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์